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frequently about 2 years after the development of PSCR, is an
11–13ickle cell disease (SCD) is caused by a single point mutation
t the sixth position in the -globin chain that substitutes
he amino acid valine for glutamic acid resulting in sickle
emoglobin (Hb S). Despite being characterized by the same
oint mutation, the clinical course of SCD is extremely
ariable, ranging from mild to very severe depending on the
ifferent genotypes.1–4 Patients with sickle cell anemia (SCA),
he most common and most severe form of SCD, have two
opies of the altered gene, a genotype referred to as Hb SS.
emoglobin C (Hb C) occurs frequently in compound heterozy-
osity with Hb S with the resulting SC disease (Hb SC) being
elatively more  benign than homozygous Hb SS. However, for
easons not well understood, these patients are more  likely to
e affected by thromboembolic complications, renal papillary
ecrosis and retinopathy.5,6
Both the anterior and posterior segments of the eye can
e compromised due to the pathological processes of SCD
ut ocular manifestations in the retina are considered the
ost important in terms of frequency and visual impairment.7
ickle cell retinopathy develops in up to 42% of individ-
8als during the second decade of life. It is triggered by
aso-occlusion of the ocular microvasculature, as opposed to
iabetic retinopathy which is associated with overexposure of
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eserved.the vascular tissues to hyperglycemia, and may lead to visual
impairment depending on its localization and affected tissue.
Sickle cell retinopathy can be classiﬁed as non-proliferative or
proliferative. In the non-proliferative form the most common
clinical ﬁndings are salmon patch hemorrhages, iridescent
spots and black sunbursts, which can be observed in the
peripheral retina. Moreover, venous tortuosity, enlargement
of the foveal avascular zone, central retinal artery obstruction
and peri-papillary and peri-macular arteriolar occlusions have
been reported in the central part of the retina. Angioid streaks
can be observed in association with sickle cell-thalassemia
disease, SCA and SCD.9,10
Proliferative sickle cell retinopathy (PSCR) complications
are a major contributor to vision loss, leading to visual impair-
ment in 10–20% of affected eyes. There is a low frequency
of visual loss in SCD which may be explained, at least in
part, by the high frequency of spontaneous regression (20–60%
of cases) through the development of atrophic lesions or
autoinfarction. Spontaneous regression, which occurs mostamp), Centro de Biologia Molecular e Engenharia Genética, Rua
important determinant in the natural history of PSCR. The
highest prevalence of PSCR in SCA patients occurs between 25
and 39 years of age in both men  and women. However, in SCD
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
oter.
r
1
1
1320  rev bras hematol hem
patients it occurs earlier: between 15 and 24 years in men  and
from 20 to 39 years in women.13 Peripheral retinal neovas-
cularization develops after vaso-occlusion of the peripheral
retina and grows anteriorly from perfused to non-perfused
retina.14 Initially these new vessels are ﬂat and denominated
sea fan for their close resemblance to the marine inverte-
brate Gorgonia ﬂabellum. Neovascularization in sea fans, even
small sea fans, is capable of causing vitreous hemorrhage. This
complication happens due to the constant leaking of blood
components into the vitreous through the fragile neovascu-
lar tissue. The repetition of this hemorrhagic phenomenon
leads to worsening of the vitreo-retinal traction, with the
potential of causing rhegmatogeneous or tractional retinal
detachment.12,15
It is important to note that there is an inverse relation-
ship between the severity of systemic disease and the severity
of retinopathy in homozygous SS individuals compared to
compound heterozygous SC subjects. Sickle cell patients have
more  systemic complications with multiple vaso-occlusive
events and secondary organ damage. Heterozygous patients,
on the other hand, have fewer systemic complications, but an
increased frequency and early onset retinal neovasculariza-
tion. According to a longitudinal study developed over 20 years
in Jamaica, the prevalence of PSCR was greater in SCD patients.
The authors reported that PSCR had developed by the age of 24
years in 43% and 14% of subjects with Hb SC disease and SCA,
respectively.12 The high prevalence of retinopathy observed in
Hb SC patients may be the consequence of this more  benign
genotype. The postulated mechanism of action is that an
enhanced circulatory competence of Hb SC cells would pre-
serve the retinal circulation allowing posterior development
of proliferative lesions.16 On the other hand, in SCA patients
there is an early and a more  complete occlusion of peripheral
retinal vessels and hence further retinal vascular damage and
proliferative lesions are rare. This phenomenon may explain
why a benign genotype such as SC disease presents a higher
frequency of PSCR compared with the SS genotype. One possi-
ble explanation proposed by Fabri and Kaul is based on three
models with different vaso-occlusive tendencies. These mod-
els are based on low, intermediate and high vaso-occlusive
indices, with SC disease being represented by the intermediate
model, that is, with vaso-occlusion sufﬁcient to produce reti-
nal ischemia, but insufﬁcient to occlude the developing PSCR
lesions.13,17
The article entitled “Sickle cell disease retinopathy: char-
acterization among pediatric and teenage patients from
northeastern Brazil” by Oliveira et al. and published in this
edition of the Revista Brasileira de Hematologia e Hemoterapia
describes a population of SCD patients from the state of Bahia,
according to their ophthalmologic characteristics.18 The main
point of the study is the conﬁrmation that retinal changes have
early onset in both SCA and SC disease patients. Their ﬁnd-
ings corroborate previous reports in different populations and
conﬁrm the need for ophthalmological monitoring of patients
from early childhood in order to avoid visual impairment as
PSCR is usually asymptomatic until complications such as
vitreous hemorrhage or retinal detachment occur.
In addition to the eye examination, it is important to note
the presence of factors that increase the chance of developing
SCPR as has been reported by other research groups. In SCD
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patients, pain crisis, male gender and splenic sequestration
suggest the need for earlier ophthalmic screening. Character-
istics of PSCR, such as neovascular and ﬁbrous proliferations
(sea fan), vitreous hemorrhage and retinal detachment, are
associated with older age, pulmonary disease, deafness or
tinnitus and no history of osteomyelitis in patients with SC
disease. In SCA patients, older age, male gender and history
of acute pyelonephritis were associated with the develop-
ment of PSCR.19–21 Regarding laboratory ﬁndings, high total
hemoglobin in males and low fetal hemoglobin in both males
and females were observed in SCA patients. In SCD patients,
increased mean cell volume and low fetal hemoglobin were
reported in both genders and high total hemoglobin and high
mean corpuscular hemoglobin concentration were observed
in men.7,13,14,22
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